blog details

Patients with life-threatening diseases like cancer 🎗, HIV 🧬, and rare genetic diseases 🧪 are likely to get relief from high medicine prices 💰 soon. A panel 🏛 formed by the government has suggested a customs duty exemption 🚫💸 on around 200 essential medicines 💊, including several high-priced cancer drugs 🎯. A report 📰 said the proposal recommended completely removing import duties 🚢💵 on some essential medicines that are currently cost prohibitive for most patients in India 🇮🇳.

🎗 Cancer Patients Will Benefit from Duty-Free Imports

The panel recommended an entire customs duty exemption 🚫💸 for three important cancer drugs:

• Pembrolizumab (Keytruda) 💉
• Osimertinib (Tagrisso) 💊
• Trastuzumab Deruxtecan (Enhertu) 🩺

These medicines are commonly used to treat cancer, especially in advanced stages ⚠. Most patients in India cannot get these top medicines due to high prices 📈, some costing lakhs 💵 for one dose 💉. This recommendation hopes to address the high costs for patients in dire need ❤️ of life-saving treatment.

The Drug Controller General of India (DCGI) 🏢 planned the panel in August 2024 📅 to investigate the potential economic implications 📊 of pricey pharmaceuticals 💊 for people with critical conditions.

🩺 Beyond Cancer: Relief for Other Critical Diseases

The exemptions that are being proposed are not limited to cancer drugs. The panel has also expanded its recommendations to include:

• Transplant medicines 🫀
• Critical care medicines 🏥
• Advanced diagnostic kits 🧪 (either imported 🚢 or unavailable in India 🇮🇳)

These initiatives would benefit not just cancer patients 🎗, but also transplant patients 🫁 or those in urgent medical care 🚑. Further, advanced diagnostic kits 🔬 for early disease detection 🩻 could see price drops 📉 if the recommendations are implemented.

🌍 Drugs for Rare Diseases Included in the List

The panel’s recommendation also includes medicines used in treating rare diseases 🧬, which are notoriously costly 💸.
Of the 200 medicines listed:

• 56 medicines 🧾 are exempt for rare disorders
• Includes treatments for:
  • Spinal Muscular Atrophy (SMA) 🦴
  • Cystic Fibrosis 🫁
  • Gaucher Disease 🧪
  • Fabry Disease 🩸
  • Lysosomal Storage Disorders 🧬
  • Hereditary enzyme deficiencies ⚗

📑 Customs Duty List Analysis

The panel classified the medicines into:

• 69 medicines with full duty exemption 🚫💸
• 74 medicines with 5% duty 💵
• 56 medicines for rare disorders 🧬

Examples:

• Hydroxyurea 💊 for cancer & sickle cell disease 🩸
• Enoxaparin 💉 for preventing blood clots 🩹 / DVT 🦵

The government’s objective 🎯 is to cut treatment prices 📉 and improve patient access 🚪 to essential products.

🏛 Permanent Committee for Ongoing Review

• To be under DGHS 🏢
• Will review the essential medicines list 📋 regularly
• Provide recommendations 💡 to Department of Revenue 📜

This ongoing review 🔄 will help update the list according to evolving health issues 🩺 and keep vital medicines affordable 💰.

💡 A Possible Lifeline for Patients

If this proposal goes ahead ✅, it could:

• Reduce medicine costs by lakhs or crores 💵
• Relieve family financial burdens ❤️
• Improve treatment access 🚑 and outcomes 📈

Healthcare professionals 👩‍⚕️👨‍⚕️ believe this is a vital first step towards affordable healthcare 🏥. For many patients — especially with rare diseases 🌍 or advanced cancers 🎗 — this could be the difference between life ❤️ and death ⚠.